[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588266":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":49,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":20,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":20,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":77,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Tianjin Huanhu Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"UCAR T-cell group","EXPERIMENTAL","Universal allogeneic CD19\u002FBCMA CAR T-cells",[13],"Drug: UCAR T-cell",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","UCAR T-cell","Universal allogeneic anti-CD19\u002FBCMA CAR T-cells",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Jialing Wu","CONTACT","86-18622271026","wywjl2009@hotmail.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Guanen Zhou","86-13920273016","tjzge@163.com",[32],{"facility":5,"status":33,"city":34,"state":20,"zip":20,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Tianjin","China","CN",{"type":38,"coordinates":39},"Point",[40,41],117.17667,39.14222,{"lat":41,"lon":40},[44,45,46,48],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":20,"role":24,"phone":20,"phoneExt":20,"email":30},{"name":23,"role":47,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"name":28,"role":47,"phone":20,"phoneExt":20,"email":20},{"type":47,"investigatorFullName":23,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Principal Investigator",[52],{"name":53,"class":54},"Shanghai Xiniao Biotech Co., Ltd.","INDUSTRY","100588266","early-phase-1-universal-chimeric-antigen-receptor-t-cell-ucar-t-cell-therapy-targeting-cd19b-cell-maturation-antigen-cd19bcma-in-patients-with-rr-neurological-autoimmune-diseases-100588266",false,"NCT06939166","Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19\u002FB Cell Maturation Antigen （CD19\u002FBCMA） in Patients With r\u002Fr Neurological Autoimmune Diseases","A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapsed \u002F Refractory Neurological Autoimmune Diseases","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Flow cytometry detected positive B cell CD19 or BCMA in the patient's peripheral blood.\n* Subjects with relapsed or refractory neurological autoimmune diseases, Including neuromyelitis optica spectrum disorders(NMOSD), myasthenia gravis(MG), multiple sclerosis(MS)，Autoimmune encephalitis(AE) and chronic inflammatory demyelinating Polyradiculoneuropathy(CIDP).\n* Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating.\n* Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n* Subjects with a history of severe drug allergies or allergic tendencies.\n* History of malignancy within five years.\n* Subjects with insufficient cardiac function.\n* Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA \\>the upper limit of detection; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV) antibody; individuals positive for syphilis testing.\n* Pregnant women or women planning to conceive.","ALL","18 Years",{"count":65,"type":66},12,"ESTIMATED","INTERVENTIONAL",[69],"EARLY_PHASE1","This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19\u002FBCMA CAR T-cells.",[72,73,74,75,76],"Neuromyelitis Optica Spectrum Disorders","Myasthenia Gravis","Multiple Sclerosis","Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Autoimmune Encephalitis",[78],"Universal Allogeneic CAR T-cells","2025-12-11",{"date":81,"type":82},"2025-12-15","ACTUAL",{"date":84,"type":82},"2025-06-17",{"date":86,"type":66},"2027-10",{"name":5,"class":6},1]